Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

DSpace Repositorium (Manakin basiert)

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

Autor(en): Hehlmann, Ruediger; Mueller, Martin C.; Lauseker, Michael; Hanfstein, Benjamin; Fabarius, Alice; Schreiber, Annette; Proetel, Ulrike; Pletsch, Nadine; Pfirrmann, Markus; Haferlach, Claudia; Schnittger, Susanne; Einsele, Hermann; Dengler, Jolanta; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; Kneba, Michael; Stegelmann, Frank; Pfreundschuh, Michael; Waller, Cornelius F.; Spiekermann, Karsten; Baerlocher, Gabriela M.; Ehninger, Gerhard; Heim, Dominik; Heimpel, Hermann; Nerl, Christoph; Krause, Stefan W.; Hossfeld, Dieter K.; Kolb, Hans-Jochem; Hasford, Joerg; Saussele, Susanne; Hochhaus, Andreas
Tübinger Autor(en):
Kanz, Lothar
Erschienen in: Journal of Clinical Oncology (2014), Bd. 32, H. 5, S. 415-U51
Verlagsangabe: Amer Soc Clinical Oncology
Sprache: Englisch
Referenz zum Volltext: http://dx.doi.org/10.1200/JCO.2013.49.9020
ISSN: 0732-183X
DDC-Klassifikation: 610 - Medizin, Gesundheit
Dokumentart: Wissenschaftlicher Artikel
Zur Langanzeige

Das Dokument erscheint in: